144 related articles for article (PubMed ID: 8540726)
41. The susceptibility of Streptococcus pneumoniae to levofloxacin and other antibiotics.
Keller N; Smollen G; Davidson Y; Barzilai A; Keren G; Rubinstein E
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():1-3. PubMed ID: 10404329
[TBL] [Abstract][Full Text] [Related]
42. The activity of rifabutin against Mycobacterium leprae.
Yoder LJ; Jacobson RR; Hastings RC
Lepr Rev; 1991 Sep; 62(3):280-7. PubMed ID: 1665534
[TBL] [Abstract][Full Text] [Related]
43. Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae.
Bauernfeind A
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():77-82. PubMed ID: 10404343
[TBL] [Abstract][Full Text] [Related]
44. Comparative in-vitro activity of levofloxacin against Chlamydia spp.
Donati M; Rumpianesi F; Marchetti F; Sambri V; Cevenini R
J Antimicrob Chemother; 1998 Nov; 42(5):670-1. PubMed ID: 9848456
[No Abstract] [Full Text] [Related]
45. Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.
Palmer SM; Rybak MJ
Antimicrob Agents Chemother; 1996 Mar; 40(3):701-5. PubMed ID: 8851596
[TBL] [Abstract][Full Text] [Related]
46. [In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
Soriano A; Jurado A; Marco F; Almela M; Ortega M; Mensa J
Rev Esp Quimioter; 2005 Jun; 18(2):168-72. PubMed ID: 16130039
[TBL] [Abstract][Full Text] [Related]
47. The activity of several newer antimicrobials against logarithmically multiplying M. leprae in mice.
Burgos J; de la Cruz E; Paredes R; Andaya CR; Gelber RH
Lepr Rev; 2011 Sep; 82(3):253-8. PubMed ID: 22125933
[TBL] [Abstract][Full Text] [Related]
48. Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes.
Pendland SL; Diaz-Linares M; Garey KW; Woodward JG; Ryu S; Danziger LH
Antimicrob Agents Chemother; 1999 Oct; 43(10):2547-9. PubMed ID: 10508042
[TBL] [Abstract][Full Text] [Related]
49. [Evaluation of levofloxacin antitubercular activity in vitro and in lung tissue culture].
Sokolova GB; Kunichan AD; Litovchenko KV; Tsybanev AA
Antibiot Khimioter; 2002; 47(12):15-9. PubMed ID: 12728630
[TBL] [Abstract][Full Text] [Related]
50. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Rodríguez JC; Ruiz M; López M; Royo G
Int J Antimicrob Agents; 2002 Dec; 20(6):464-7. PubMed ID: 12458143
[TBL] [Abstract][Full Text] [Related]
51. Anaerobic activity of levofloxacin and metronidazole separately and in combination.
Barry AL; Brown SD
J Antimicrob Chemother; 1996 Jun; 37(6):1178-9. PubMed ID: 8836822
[No Abstract] [Full Text] [Related]
52. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice.
Consigny S; Bentoucha A; Bonnafous P; Grosset J; Ji B
Antimicrob Agents Chemother; 2000 Oct; 44(10):2919-21. PubMed ID: 10991891
[TBL] [Abstract][Full Text] [Related]
53. [Comparative study of the bacteriostatic and bactericidal activity of levofloxacin against Pasteurella strains isolated from man].
Heurtin C; Desbordes L; Travert MF; Donnio PY; Avril JL
Pathol Biol (Paris); 2001 Oct; 49(8):606-11. PubMed ID: 11692747
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of BACTEC 460 TB system for measurement of in vitro anti-Mycobacterium leprae activity of various antimicrobials.
Tomioka H; Saito H; Sato K
Nihon Rai Gakkai Zasshi; 1992 Nov; 61(3):157-64. PubMed ID: 1308482
[TBL] [Abstract][Full Text] [Related]
55. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates.
Bonfiglio G; Cascone C; Azzarelli C; Cafiso V; Marchetti F; Stefani S
J Antimicrob Chemother; 2000 Jan; 45(1):115-7. PubMed ID: 10629022
[TBL] [Abstract][Full Text] [Related]
56. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
Dholakia N; Rolston KV; Ho DH; LeBlanc B; Bodey GP
Antimicrob Agents Chemother; 1994 Apr; 38(4):848-52. PubMed ID: 8031057
[TBL] [Abstract][Full Text] [Related]
57. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
Rodríguez JC; Ruiz M; Climent A; Royo G
Int J Antimicrob Agents; 2001 Mar; 17(3):229-31. PubMed ID: 11282270
[TBL] [Abstract][Full Text] [Related]
58. Determination of the minimal effective dosages of ofloxacin and sparfloxacin against M. leprae in the mouse foot pad system.
Traore I; Ji B; Lienhardt C; Bobin P; Grosset J
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):142-5. PubMed ID: 8690973
[TBL] [Abstract][Full Text] [Related]
59. In-vitro activity of ofloxacin, levofloxacin and D-ofloxacin against staphylococci.
von Eiff C; Peters G
J Antimicrob Chemother; 1996 Aug; 38(2):259-63. PubMed ID: 8877540
[TBL] [Abstract][Full Text] [Related]
60. Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice.
Bermudez LE; Inderlied CB; Kolonoski P; Wu M; Barbara-Burnham L; Young LS
Antimicrob Agents Chemother; 1996 Mar; 40(3):546-51. PubMed ID: 8851568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
